** Shares of Neuren Pharmaceuticals NEU.AX up 16% at A$10.7, their biggest intraday percentage gain since December 18, 2023
** Stock is top gainer in the ASX 200 benchmark index .AXJO, which is up 0.6%
** The drugmaker says primary endpoints for its Phase 3 trial of NNZ-2591 in Phelan-McDermid syndrome (PMS), a genetic disorder, confirmed at a meeting with the U.S. Food and Drug Administration
** Stock down 26.5% this year, as of last close
(Reporting by Sherin Sunny in Bengaluru)
((Sherin.Sunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.